Abstract
Alfacalcidol is a widely used vitamin D compound, especially in clinical nephrology because it does not require enzymatic activation by the kidneys. For that reason it has been used for decades to treat abnormalities in bone and mineral balance that arise in chronic kidney disease. In this review an overview is provided of available experimental and clinical data that form the basis of its widespread use. Supported by studies on cell lines and animal models, clinical studies have firmly established beneficial effects of alfacalcidol on chronic-kidney disease (CKD-) related bone disease and secondary hyperparathyroidism. Its effects on muscle structure and function are not unambiguous. Neither experimental nor clinical data suggest beneficial effects of alfacalcidol on indicators of cardiovascular disease, including cardiovascular calcification, left ventricular mass function or hypertension. Suggestions of improved mortality in dialysis patients treated with alfacalcidol are based on observational cohort analyses. Integrating all available data leads the conclusion that alfacalcidol is a justifiable compound to prescribe to CKD patients with established bone disease or hyperparathyroidism. Monitoring of calcium and phosphorus levels after its initiation is required and dose adaptations should be made accordingly.
Keywords: Alfacalcidol, bone mineral density, chronic kidney disease, cardiovascular disease, CKD-MBD, secondary hyperparathyroidism, vitamin D.
Current Vascular Pharmacology
Title:Clinical Uses of 1-alpha-hydroxycholecalciferol
Volume: 12 Issue: 2
Author(s): Marc Vervloet
Affiliation:
Keywords: Alfacalcidol, bone mineral density, chronic kidney disease, cardiovascular disease, CKD-MBD, secondary hyperparathyroidism, vitamin D.
Abstract: Alfacalcidol is a widely used vitamin D compound, especially in clinical nephrology because it does not require enzymatic activation by the kidneys. For that reason it has been used for decades to treat abnormalities in bone and mineral balance that arise in chronic kidney disease. In this review an overview is provided of available experimental and clinical data that form the basis of its widespread use. Supported by studies on cell lines and animal models, clinical studies have firmly established beneficial effects of alfacalcidol on chronic-kidney disease (CKD-) related bone disease and secondary hyperparathyroidism. Its effects on muscle structure and function are not unambiguous. Neither experimental nor clinical data suggest beneficial effects of alfacalcidol on indicators of cardiovascular disease, including cardiovascular calcification, left ventricular mass function or hypertension. Suggestions of improved mortality in dialysis patients treated with alfacalcidol are based on observational cohort analyses. Integrating all available data leads the conclusion that alfacalcidol is a justifiable compound to prescribe to CKD patients with established bone disease or hyperparathyroidism. Monitoring of calcium and phosphorus levels after its initiation is required and dose adaptations should be made accordingly.
Export Options
About this article
Cite this article as:
Vervloet Marc, Clinical Uses of 1-alpha-hydroxycholecalciferol, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/15701611113119990132
DOI https://dx.doi.org/10.2174/15701611113119990132 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: [Hot Topic: Nanotechnology and Patents in Agriculture, Food Technology, Nutrition and Medicine - Advantages and Risks]
Recent Patents on Food, Nutrition & Agriculture Editorial
Current Rheumatology Reviews Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
Current Diabetes Reviews Strategies of Functional Foods Promote Sleep in Human Being
Current Signal Transduction Therapy Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets The Effect of Positive Mental Imagery on Labor Pain Tolerance in Primiparous Women Referred to Atieh Hospital of Hamadan, Iran, 2018: A Randomized Controlled Clinical Trial Study
Current Women`s Health Reviews Novel Approaches to Target Pancreatic Cancer
Current Cancer Drug Targets Radziszewski Reaction: An Elegant, Easy, Simple and Efficient Method to Synthesise Imidazoles
Current Organic Synthesis Clinical Presentation, Quality of Care, Risk Factors and Outcomes in Women with Acute ST-Elevation Myocardial Infarction (STEMI): An Observational Report from Six Middle Eastern Countries
Current Vascular Pharmacology The Relationship Between Inflammation, Platelet Activation and Antiplatelet Resistance
Inflammation & Allergy - Drug Targets (Discontinued) Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review
Current Cardiology Reviews Challenging the Evidence Based Medicine Principles Among Clinical Obesity Treatments
Current Clinical Pharmacology Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) COXIBs, CINODs and H2S-Releasing NSAIDs: Current Perspectives in the Development of Safer Non Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Xanthan Gum and Its Derivatives as a Potential Bio-polymeric Carrier for Drug Delivery System
Current Drug Delivery Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders